Renaissance Technologies LLC Grows Stock Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Renaissance Technologies LLC raised its holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 99.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 624,500 shares of the company's stock after purchasing an additional 310,800 shares during the quarter. Renaissance Technologies LLC owned 0.88% of Ventyx Biosciences worth $1,368,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Catalina Capital Group LLC purchased a new stake in Ventyx Biosciences during the fourth quarter worth $25,000. AXQ Capital LP purchased a new stake in shares of Ventyx Biosciences during the 4th quarter worth about $29,000. Palumbo Wealth Management LLC grew its position in shares of Ventyx Biosciences by 97.1% during the 4th quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company's stock valued at $52,000 after acquiring an additional 11,792 shares during the period. Wells Fargo & Company MN increased its stake in shares of Ventyx Biosciences by 23.3% in the 4th quarter. Wells Fargo & Company MN now owns 41,170 shares of the company's stock valued at $90,000 after purchasing an additional 7,768 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in Ventyx Biosciences by 12.4% in the 4th quarter. American Century Companies Inc. now owns 67,329 shares of the company's stock worth $147,000 after purchasing an additional 7,414 shares during the period. 97.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "neutral" rating on shares of Ventyx Biosciences in a research report on Tuesday, January 14th.

Ventyx Biosciences Stock Performance

Shares of VTYX traded up $0.07 during mid-day trading on Friday, hitting $1.45. 1,265,706 shares of the company were exchanged, compared to its average volume of 1,278,028. Ventyx Biosciences, Inc. has a 1-year low of $0.78 and a 1-year high of $5.66. The stock has a market cap of $103.18 million, a price-to-earnings ratio of -0.61 and a beta of 0.75. The company has a 50 day moving average of $1.24 and a 200-day moving average of $1.83.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.13. Research analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.